MAPT yields 1000000.00% · ABBV yields 3.12%● Live data
📍 MAPT pulled ahead of the other in Year 1
Combined, MAPT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MAPT + ABBV for your $10,000?
Maptelligent, Inc. provides cloud based geographic platform. Its geographic platform integrates disparate data from sensors, cameras, alarms, and access control and accountability systems to create actionable intelligence on an intuitive map interface, as well as provides access information relevant to structures and sites that enhances situational awareness and emergency response while en route and upon arrival at the incident scene to mitigate additional loss of life and property of incidents occurring within buildings when shared with first responders. The company also provides a suite of maps and apps, which offers customers the ability to maintain and manage data in a mobile environment for public safety to create incident pre-plans associated with the building floor plan, as well as for building engineers to manage maintenance schedules for critical elements of a building, such as alarm panels, pull stations, extinguishers, and other assets, which need regular attention. In addition, it offers professional services (ProServ) to build high fidelity floor plans, safety assessments, and system integration services; and a cloud content management solution to store and manage data associated with the security solutions. The company serves organizations and entities, who are often at risk from threats and emergency incidents, such as schools, universities, hospitals, shopping malls, sporting events, commercial enterprises, and ports. Maptelligent, Inc. is based in Henderson, Nevada.
Full MAPT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.